Shaily Engineering Capitalizes on Semaglutide Boom to Surpass Market Expectations

Shaily Engineering Plastics Sees Stock Surge Amid Global Scramble for Semaglutide

Shaily Engineering Plastics, a precision components maker, has witnessed a significant surge in its stock price due to its involvement in the global rush to deliver semaglutide, a blockbuster anti-obesity and diabetes drug. The company's rise is not directly tied to the drug itself but rather to the precision-engineered injector pens used to administer it.

As patents for semaglutide begin to expire across various markets, including India, Canada, and Brazil, generic drugmakers are racing to launch alternatives. Shaily Engineering has emerged as a critical partner in this endeavor, providing its precision-engineered device to generic drugmakers. The company's chief strategy officer, Sanjay Shah, has stated that one of their customers has already received approval in Canada for generic semaglutide with their device, which they have designed, hold intellectual property for, and manufacture in India.

This milestone is significant as developed markets like Canada demand stringent regulatory standards. The approval is a validation of the device and of Indian engineering capabilities. Shaily took a contrarian bet on drug-delivery devices years earlier, investing three to five years in developing its pen technology instead of licensing it.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

When Shaily started developing its pen technology, they did not anticipate the GLP1 market would be as big as it is today. However, they took the risk and built a full-stack capability, including design through a UK subsidiary, and created global intellectual property for the device. This advantage is critical for drugmakers as semaglutide is a combination product, requiring both the drug and the delivery device to be approved together.

Shaily's involvement in the semaglutide market has positioned the company as a preferred partner for Indian and global pharma companies racing to launch generics. The company is working with multiple customers in India and globally and expects demand to grow as more markets go off patent.

Brokerage UBS has identified Shaily as its "top midcap idea" for 2026, citing the company's structural growth story. Shaily is well-positioned to benefit from the launch of generic semaglutide, and the market has yet to fully price in its potential.

Financial Highlights

Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline

Driven by pen injectors, Shaily's healthcare vertical surged 139% in the past year, more than doubling its revenue contribution to 40%. The segment is now the company's primary growth engine.

Shaily is investing aggressively to capture the demand for its pen injectors. The company is raising capacity to up to 85 million pens annually in India, with additional lines coming online this fiscal. It is also building a 75-million-pen capacity plant in Abu Dhabi, as part of a diversification strategy.

Shaily has already invested about Rs 400 crore in India and plans to spend Rs 2,50,350 crore in Abu Dhabi, taking overall investments to around Rs 7,50,800 crore. The expansion is backed by strong visibility, with a Rs 423-crore order for pen injectors disclosed alongside multiple ongoing customer engagements.

While there are risks associated with the business, including timely regulatory approvals and execution of complex manufacturing lines, the opportunity appears outsized. Shaily has carved out a niche for itself in the market by developing its intellectual property and aligning early with generic pharma players. This combination could translate into sticky, long-term relationships as the semaglutide opportunity unfolds.